 |
|
|
|
 |
|
|
| Article 1 to 9 out of 9 concerning Enzo Biochem, Inc.
|
-
Enzo named senior party in interference for patent of basic DNA gel sequencing
(21 Nov 2006)
Enzo Biochem, Inc. announced that the United States Patent and Trademark Office has declared a patent interference between an allowed patent application of its subsidiary, Enzo Life Sciences, Inc., and a patent held by California Institute of ...
-
Enzo Biochem Appoints Carl W. Balezentis, Ph.D., President Of Enzo Life Sciences Subsidiary
(12 Jun 2006)
Enzo Biochem, Inc. announced the appointment of Carl W. Balezentis, Ph.D. to the newly created position of President of Enzo Life Sciences, Inc. Dr. Balezentis, a senior executive with 18 years experience in the life sciences industry, was CEO of ...
-
Enzo Biochem Plans To Produce Single Copy DNA Probes For More Effective Treatment Of Genetic Diseases And Cancer
(26 May 2006)
Enzo Biochem Inc. announced that, as a result of a licensing agreement, it plans to enter into the cytogenetics market by producing newly patented single copy DNA probes that can identify the minutest strands of DNA, opening the door to more ...
-
Enzo Biochem Initiates Phase II Trial Of Immunomodulatory Compound For Crohn's Disease
(20 Mar 2006)
Enzo Biochem, Inc. announced that its wholly owned subsidiary Enzo Therapeutics has initiated a Phase II clinical trial to evaluate its immunomodulatory candidate drug EGS21 as a therapeutic for managing Crohn's disease. A Phase I safety trial of ...
-
Enzo Awarded Patent For Phosphate Labeling For DNA Diagnostic And Medical Research Products
(24 Feb 2006)
Enzo Biochem, Inc. announced that its subsidiary, Enzo Life Sciences, Inc., has been granted U.S. Patent No. 6,992,180, entitled "Oligo-or polynucleotides comprising phosphate-moiety labeled nucleotides," describing techniques applicable to a wide ...
-
Enzo Biochem Awarded $1 Million Grant To Fund Clinical Trial Of Liver Disease Treatment
(13 Jan 2005)
Enzo Biochem, Inc. announced that it has received a $1 million grant from the Israel-U.S. Binational Industrial Research and Development Foundation (BIRD) to fund a clinical trial to evaluate the efficacy of the Company's new immunomodulatory agent ...
-
Enzo Life Sciences Launches New Advanced Amplification Technology For Gene Expression Analysis Studies
(15 Nov 2004)
Changes Paradigm of Gene Expression Microarray Analysis And Overcomes Limitations of Standard Methods
The wholly owned subsidiary of Enzo Biochem, Enzo Life Sciences, has launched a new amplification method aimed at improving gene expression data derived from microarray experiments.The relatively large amounts of RNA sample required to carry out ...
-
Enzo Biochem Granted European Patent For Displacer Technology To Treat Gene Abnormalities
(15 Jun 2004)
Methodology Could Make Possible Modification or Corrections of Cell Mutations
Farmingdale. Enzo Biochem, Inc. , announced that the European Patent Office has granted it a patent that describes, in part, a method of performing targeted delivery and incorporation of genetic material into chromosomal DNA without using a viral ...
-
Enzo rejects Roche settlement offer - Roche responds with lawsuit
(04 Jun 2004)
Farmingdale. Enzo Biochem, Inc. announced that after it rejected as inadequate the latest cash offer by Roche Diagnostics GmbH to settle Enzo's claims for, inter alia, alleged breach of contract and misappropriation of Enzo's assets, Roche ...
|
|
|
|
|
Top
